Abeona Therapeutics (ABEO) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 12, 2026, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 11, 2026.

Voting matters and shareholder proposals

• Election of three Class 1 Directors for a three-year term: Michael Amoroso, Keith A. Goldan, and Bernhardt G. Zeiher, M.D.

• Advisory vote to approve named executive officer compensation.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Proposal to increase shares reserved under the 2023 Equity Incentive Plan from 8,400,000 to 11,500,000.

• Amendment to Restated Certificate of Incorporation to remove advance notice provision for director nominations.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and governance amendments.